[Pre-Aug 2018] IMSCAR

  1. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  2. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  3. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  4. Cyhoeddwyd

    Abolition of prescription charges in Wales: the impact on medicines use in those who used to pay

    Hughes, D., Groves, S., Cohen, D., Alam, M. F., Dunstan, F. D., Routledge, P. A., Hughes, D. A. & Myles, S., 1 Rhag 2010, Yn: International Journal of Pharmacy Practice. 18, 6, t. 332-340

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  5. Cyhoeddwyd

    Abolition of prescription copayments in Wales: an observational study on dispensing rates.

    Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Awst 2010, Yn: Value in Health. 13, 5, t. 675-680

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  6. Cyhoeddwyd

    Access to timely care in Portugal as compared to other European countries

    Woods, R. T., Pereira, M. G., Stephan, A., Verhey, F., de Vugt, M., Wolfs, C., Handels, R., Verbeek, H., Kerpershoek, L., Bieber, A., Meyer, G., Marques, M., Barrios, H., Balsinha, C., Woods, R., Wimo, A., Selbaeck, G., Irving, K. & Zannetti, O., 1 Rhag 2015, Yn: International Psychogeriatrics. 27, 1, t. S35-S36

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  7. Cyhoeddwyd

    Accounting for non-compliance in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 12, t. 1185-1197

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  8. Cyhoeddwyd

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  9. Cyhoeddwyd

    Activity Increase Despite Arthritis (AÏDA): design of a Phase II randomised controlled trial evaluating an active management booklet for hip and knee osteoarthritis [ISRCTN24554946]

    Williams, N., Amoakwa, E., Burton, K., Hendry, M., Belcher, J., Lewis, R., Hood, K., Jones, J. G., Bennett, P., Edwards, R. T., Neal, R., Andrew, G. & Wilkinson, C., 4 Medi 2009, Yn: BMC Family Practice. 10, 62, t. 1-9 62.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  10. Cyhoeddwyd

    Activity Increase Despite Arthritis (AÏDA): phase II randomised controlled trial of an active management booklet for hip and knee osteoarthritis in primary care

    Williams, N. H., Amoakwa, E., Belcher, J., Edwards, R. T., Hassani, H., Hendry, M., Burton, K., Lewis, R., Hood, K., Jones, J., Bennett, P., Linck, P. G., Neal, R. D. & Wilkinson, C. E., 1 Awst 2011, Yn: British Journal of General Practice. 61, 589, t. e452-e458

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  11. Cyhoeddwyd

    Additional therapy for young children with spastic cerebral palsy: a randomised controlled trial.

    Weindling, A. M., Cunningham, C. C., Glenn, S. M., Edwards, R. T. & Reeves, D. J., 1 Mai 2007, Yn: Health Technology Assessment. 11, 16, t. 90

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  12. Cyhoeddwyd

    Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis

    Bellis, M. A., Williams, R., Aspinall, R., Bellis, M., Camps-Walsh, G., Cramp, M., Dhawan, A., Ferguson, J., Forton, D., Foster, G., Gilmore, I., Hickman, M., Hudson, M., Kelly, D., Langford, A., Lombard, M., Longworth, L., Martin, N., Moriarty, K., Newsome, P., O'Grady, J. & Pryke, R., 27 Tach 2014, Yn: The Lancet. 384, 9958, t. 1953-1997

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  13. Cyhoeddwyd

    Adherence and variability in warfarin dose requirements: assessment in a prospective cohort

    Hughes, D., Jorgensen, A. L., Hughes, D. A., Hanson, A., van Eker, D., Toh, C. H., Pirmohamed, M. & Williamson, P. R., 1 Ion 2013, Yn: Pharmacogenomics. 14, 2, t. 151-163

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  14. Cyhoeddwyd

    Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria

    Lotsch, F., Auer-Hackenberg, L., Groger, M., Rehman, K., Morrison, V. L., Holmes, E. A., Parveen, S., Plumpton, C. O., Clyne, W., de Geest, S., Dobbels, F., Vrijens, B., Kardas, P., Hughes, D. & Ramharter, M., Mai 2015, Yn: Wiener klinische Wochenschrift. 127, 9-10, t. 379-384

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  15. Cyhoeddwyd

    Adherence with HAART: pharmacoeconomic considerations

    Hughes, D. & Hughes, D. A., 1 Meh 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  16. Cyhoeddwyd

    Adverse childhood experiences and associations with health-harming behaviours in young adults: surveys in eight eastern European countries

    Bellis, M. A., Hughes, K., Leckenby, N., Jones, L., Baban, A., Karcheva, M., Povilaitis, R., Pudule, I., Qirjako, G., Ulukol, B. & Raleva, M. T., 19 Meh 2014, Yn: Bulletin of the World Health Organization. 92, t. 641-655B

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  17. Cyhoeddwyd

    Adverse childhood experiences: retrospective study to determine their impact on adult health behaviours and health outcomes in a UK population.

    Bellis, M. A., Lowey, H., Leckenby, N., Hughes, K. & Harrison, D., 14 Ebr 2013, Yn: Journal of Public Health. 36, 1, t. 81-91

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  18. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Gorff 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  19. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  20. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  21. Cyhoeddwyd

    Adverse drug reactions: analysis by regulatory authorities and by economists

    Hughes, D. & Hughes, D. A., 1 Ebr 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  22. Cyhoeddwyd

    Alcohol age of initiation and long-term impact: a cross sectional survey of adults in England

    Morleo, M., Jones, L. & Bellis, M. A., 30 Hyd 2014, Yn: Journal of Substance Use.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  23. Cyhoeddwyd
  24. Cyhoeddwyd
  25. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  26. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  27. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  28. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  29. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  30. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  31. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  32. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  33. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  34. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  35. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  36. Cyhoeddwyd
  37. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  38. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  39. Cyhoeddwyd
  40. Cyhoeddwyd
  41. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  42. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  43. Cyhoeddwyd
  44. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  45. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  46. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  47. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  48. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  49. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  50. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn